Skip to main content
Premium Trial:

Request an Annual Quote

Cerep Inks Kinase-Profiling Agreement with Lilly

NEW YORK (GenomeWeb News) - Cerep today said that it has signed an agreement with Eli Lilly & Co. covering the use of its kinase assay platform to study undisclosed drug targets.

The agreement is an extension of an existing deal between the two companies for access to Cerep's GPCR screening portfolio.

Cerep's kinase profiling service is based on PerkinElmer's Lance Ultra kinase assay technology.

Cerep's kinase platform includes screening capabilities for 250 targets with assays for cancer, cardiac diseases, central nervous system disorders, inflammation, diabetes, metabolic disorders, and other disease states, the company said.

Financial terms of the agreement were not provided.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more